Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics.
The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.
It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases.
In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system.
It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer.
Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 8, 24 | -1.52 Decreased by -8.57% | -1.23 Decreased by -23.58% |
| May 9, 24 | -1.12 Increased by +4.27% | -1.38 Increased by +18.84% |
| Feb 22, 24 | -1.46 Decreased by -4.29% | -1.45 Decreased by -0.69% |
| Nov 9, 23 | -1.38 Increased by +7.38% | -1.50 Increased by +8.00% |
| Aug 3, 23 | -1.40 Decreased by -5.26% | -1.32 Decreased by -6.06% |
| May 4, 23 | -1.17 Increased by +40.31% | -1.40 Increased by +16.43% |
| Feb 23, 23 | -1.40 Decreased by -28.44% | -1.39 Decreased by -0.72% |
| Nov 3, 22 | -1.49 Decreased by -53.61% | -1.28 Decreased by -16.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 9.11 M Decreased by -24.02% | -135.71 M Decreased by -11.04% | Decreased by -1.49 K% Decreased by -46.15% |
| Jun 30, 24 | 6.96 M Decreased by -48.82% | -146.97 M Decreased by -18.83% | Decreased by -2.11 K% Decreased by -132.20% |
| Mar 31, 24 | 28.93 M Increased by +129.53% | -107.44 M Decreased by -16.34% | Decreased by -371.30% Increased by +49.31% |
| Dec 31, 23 | -1.92 M Decreased by -114.12% | -132.16 M Decreased by -13.22% | Increased by +6.89 K% Increased by +901.65% |
| Sep 30, 23 | 11.99 M Decreased by -9.60% | -122.22 M Decreased by -9.83% | Decreased by -1.02 K% Decreased by -21.50% |
| Jun 30, 23 | 13.59 M Decreased by -3.11% | -123.68 M Decreased by -23.71% | Decreased by -909.82% Decreased by -27.68% |
| Mar 31, 23 | 12.61 M Increased by +12.03% | -92.34 M Increased by +37.13% | Decreased by -732.54% Increased by +43.88% |
| Dec 31, 22 | 13.57 M Increased by +5.59% | -116.73 M Decreased by -43.69% | Decreased by -859.99% Decreased by -36.08% |